Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Edgestream Partners L.P.

Edgestream Partners L.P. cut its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 42.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 26,417 shares of the company's stock after selling 19,869 shares during the quarter. Edgestream Partners L.P.'s holdings in Moderna were worth $1,098,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of MRNA. State Street Corp raised its stake in shares of Moderna by 12.1% in the third quarter. State Street Corp now owns 16,847,212 shares of the company's stock valued at $1,125,899,000 after acquiring an additional 1,823,276 shares in the last quarter. Geode Capital Management LLC raised its position in Moderna by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company's stock valued at $470,670,000 after purchasing an additional 178,115 shares in the last quarter. Wellington Management Group LLP raised its position in Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company's stock valued at $349,166,000 after purchasing an additional 906,114 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Moderna by 0.5% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company's stock worth $260,023,000 after buying an additional 19,819 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in shares of Moderna by 6.2% during the third quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company's stock worth $205,431,000 after buying an additional 178,939 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.

Moderna Trading Down 6.1 %

Moderna stock opened at $33.76 on Wednesday. The firm has a market capitalization of $13.03 billion, a P/E ratio of -3.64 and a beta of 1.86. The stock has a fifty day moving average price of $36.38 and a 200 day moving average price of $48.11. Moderna, Inc. has a 52 week low of $29.25 and a 52 week high of $170.47.

Wall Street Analyst Weigh In

Several research analysts have commented on MRNA shares. JPMorgan Chase & Co. set a $45.00 price target on shares of Moderna in a report on Friday, February 14th. UBS Group lowered their target price on shares of Moderna from $96.00 to $78.00 and set a "buy" rating for the company in a research note on Wednesday, February 19th. Piper Sandler restated an "overweight" rating and issued a $69.00 price target (down from $115.00) on shares of Moderna in a research note on Monday, November 18th. Hsbc Global Res raised Moderna from a "hold" rating to a "strong-buy" rating in a research report on Monday, November 18th. Finally, Wolfe Research began coverage on Moderna in a research report on Friday, November 15th. They set an "underperform" rating and a $40.00 target price on the stock. Four equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $60.63.

Remove Ads

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.